Gapping up
In reaction to strong earnings/guidance:
- FL +20.5%, GOGO +11.4%, CEVA +9.5%, CGC +8%, SDGR +6.5%, AVYA +6.1%, TGNA +5%, ICPT +4.6%, TGTX +3.7%, AXSM +3.1%, WSC +2.2%, GOLD +1.9%, DUK +1.6%, ON +1.5%, MNTA +1.1%
Other news:
- MCRB +311.9% (announces positive topline results from SER-109 Phase 3 ECOSPOR III study)
- TRVN +55% (announces FDA approval of OLINVYK (oliceridine) injection)
- MJCO +22.6% (to be acquired by Thoma Bravo for $16.00 per share)
- IBIO +13.2% (provided an update on one of its proprietary vaccine candidates being designed to prevent infection from the SARS-CoV-2 virus)
- DOYU +11.5% (reported earnings, also - received a preliminary non-binding proposal letter, dated August 10, 2020, from Tencent Holdings Limited, proposing that DouYu and HUYA Inc. (HUYA) enter into a stock-for-stock merger)
- MNK +7.6% (announces U.S. FDA filing acceptance of Biologics License Application for StrataGraft regenerative skin tissue for treatment of adults with deep partial-thickness thermal burns)
- HUYA +7.3% (received a preliminary non-binding proposal letter, dated August 10, 2020, from Tencent Holdings Limited, proposing that DouYu and HUYA Inc. (HUYA) enter into a stock-for-stock merger)
- SNCR +6.2% (secured a renewal to its agreement to provide Verizon with its White-Label Personal Cloud Platform)
- SPG +6.1% (Simon Property Group (SPG) is in discussions with Amazon (AMZN) to turn some of its anchor store space into fulfillment centers)
- PSTI +5.9% (Paul Ehrlich Institutehas cleared the Company's Phase II clinical protocol for its study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of severe COVID-19)
- NK +5.4% (NantKwest and CBR by Generate Life Sciences announce collaboration to develop a COVID-19 treatment leveraging newborn stem cells
- TWTR +3.3% (Twitter (TWTR) and TikTok held preliminary discussions about a potential merger )
- AQST +3.3% (FDA has granted Fast Track designation for the Company's drug candidate AQST-108 for the treatment of allergic reactions (Type 1), including anaphylaxis)
- AXSM +3.1% (announces continued progress toward NDA filing of AXS-05 in the treatment of major depressive disorder)
- AAPL +1.2% (positive article in Barrons)
Analyst comments:
- AVNT +7.8% (upgraded to Buy from Hold at The Benchmark Company)
- FVRR +3.5% (upgraded to Buy from Neutral at Citigroup)
- FDX +1.9% (upgraded to Outperform from Mkt Perform at Bernstein)
- KRMD +1.6% (initiated with a Buy at H.C. Wainwright; tgt $16)
- CUBE +1% (upgraded to Outperform from In-line at Evercore ISI)